Leap Therapeutics

Leap Therapeutics is a biotechnology company focused on developing targeted and immuno-oncology therapeutics for cancer patients. Their most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, currently being developed for patients with esophagogastric, gynecologic, and colorectal cancers. Leap also has other clinical programs targeting Claudin18.2 in gastric and pancreatic cancer, and preclinical programs targeting Claudin18.2/CD137 and GDF15.

Leap emphasizes a commitment to developing personalized medicines for patients by identifying specific biomarkers to predict response and survival outcomes. The company prides itself on a collaborative and supportive work environment, offering competitive compensation and benefits to its employees. They believe in fostering a culture of trust and responsibility to achieve their mission of acquiring and developing drugs with the potential to change the practice of medicine.

Leap Therapeutics offers a hybrid work environment, which provides employees with the flexibility to work both remotely and in the office. This allows for a more flexible work-life balance, allowing employees to tailor their work schedule to their individual needs. The company also offers flexible PTO and parental leave, further demonstrating their commitment to employee well-being.

Leap Therapeutics offers a comprehensive benefits package to its employees, known as "Leapsters". These benefits include medical, dental, and vision coverage, a health savings account with employer contribution, a 401K plan with employer match, flexible spending accounts, a collaborative culture, a hybrid work environment, competitive compensation, life and disability coverage, company-sponsored events, parental leave, flexible PTO, and flexible work-life balance options.

Leap Therapeutics is a biopharmaceutical company dedicated to developing targeted and immuno-oncology therapies that have the potential to transform cancer treatment. Their mission is to acquire and develop a pipeline of drugs that can change the practice of medicine by identifying specific biomarkers to predict patient response and improve survival outcomes. They aim to be a biomarker-focused oncology drug development company, delivering personalized medicines to patients worldwide.

Leap Therapeutics fosters a culture of teamwork and professionalism, built on trust and responsibility. They value their employees ("Leapsters") and create a collaborative work environment where individuals are valued for their skills and unique perspectives. This culture prioritizes work-life balance and offers competitive benefits and a hybrid work environment.

Leap Therapeutics is committed to fostering a diverse and inclusive workplace where all employees feel valued for their skills, experience, and unique perspectives. They are an Equal Opportunity Employer, extending opportunities to all individuals regardless of race, color, creed, ancestry, national origin, citizenship, sex or gender, gender identity or expression, sexual orientation, marital status, religion, age, disability, genetic disposition, caregiver status, reproductive health decisions, or any other characteristic protected by applicable laws. This commitment is reflected in their efforts to create a culture of teamwork and professionalism, with a focus on trust and responsibility.